SCHEMBL16281235

SCHEMBL16281235

Cc1ncnc2cc(-c3ccc(Cl)cc3)sc12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 3/20 0.56
▸ NPC1 O15118 2/20 0.56
▸ KMT2A Q03164 1/20 0.56
▸ TDP1 Q9NUW8 1/20 0.56
▸ STK17B O94768 6/20 0.55
▸ MAP3K8 P41279 4/20 0.55
▸ EGFR P00533 2/20 0.53
▸ TYK2 P29597 1/20 0.50
▸ IKBKB O14920 1/20 0.48
▸ KIT P10721 1/20 0.45
▸ MCHR1 Q99705 2/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ LMNA P02545 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ TUBB4A P04350 1/20 0.43
▸ TUBB P07437 1/20 0.43
▸ TUBA3C P0DPH7 1/20 0.43
▸ TUBA1B P68363 1/20 0.43
▸ TUBA4A P68366 1/20 0.43
▸ TUBB4B P68371 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16281232 0.84 IKBKB (0.67) RAB9ANPC1KMT2ATDP1STK17B
SCHEMBL15703493 0.81 MAP3K8 (0.55) RAB9ANPC1KMT2ATDP1STK17B
SCHEMBL14090791 0.81 RAB9A (0.52) RAB9ANPC1KMT2ATDP1STK17B
SCHEMBL17268775 0.78 NPC1 (0.72) RAB9ANPC1KMT2ATDP1STK17B
SCHEMBL15721691 0.76 MAP3K8 (0.56) RAB9ANPC1KMT2ATDP1STK17B
SCHEMBL15504606 0.72 RAB9A (0.68) RAB9ANPC1KMT2ATDP1STK17B
SCHEMBL15703517 0.72 NPC1 (1.00) RAB9ANPC1KMT2ATDP1STK17B
SCHEMBL3979017 0.71 NPC1 (0.67) RAB9ANPC1KMT2ATDP1STK17B
SCHEMBL2879120 0.71 NPC1 (0.67) RAB9ANPC1KMT2ATDP1STK17B
SCHEMBL13313005 0.71 MCHR1 (0.57) MCHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160243085-A1 SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS MIDCAP FINANCIAL TRUST 2016-08-25 — — US disclosed
US-9353126-B2 Substituted triazoles useful as Axl inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2016-05-31 — — US disclosed
EP-2476679-B1 Substituted triazoles useful as AXL inhibitors RIGEL PHARMACEUTICALS INC (US) 2015-10-14 — — EP disclosed
US-20150072959-A1 SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS MIDCAP FINANCIAL TRUST 2015-03-12 — — US disclosed
US-8906922-B2 Substituted triazoles useful as AXl inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2014-12-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150072959-A1 SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS AXL, TYRO3, MERTK RAB9A 2200/4885NPC1 4152/4885KMT2A 2917/4885
US-20160243085-A1 SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS AXL, TYRO3, MERTK RAB9A 2200/4885NPC1 4152/4885KMT2A 2917/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback